EUVIMEDEUVIMED entdecken
Crossref

An Orthogonal Nanoadjuvant-Based RSV Subunit Vaccine Unlocks Potent Immunity through a High-Entropy-like Immunostimulatory Effect

Ling Chen, Yun Sun, Yuhang Dong, Yuqin Jin, Zibo Han, Ning Liu, Xiang Zheng, Shuai Shao, Jing Zhang, Yu Liang, Mingtao Pu, Meijing Du und 4 weitere

Journal of the American Chemical Society · 05.08.2026 · 148 (30) · 32863-32880

DOI: 10.1021/jacs.6c11987 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 22.07.2026. Verfasst von Ling Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Resource Engineering, College of Chemistry, Beijing University of Chemical Technology, Beijing100029, P. R. China. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Adjuvants, Immunologic, Respiratory Syncytial Virus Infections, Respiratory Syncytial Viruses. Die Arbeit nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality, Beijing University of Chemical Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) is one of the primary contributors to lower respiratory tract infections, especially in infants, children, and the elderly. The quest for a clinically acceptable and potent RSV vaccine constitutes a long-standing hurdle in clinical practice. Herein, we propose an orthogonal nanoadjuvant-based nanovaccine platform that addresses the long-standing challenge of insufficient cellular immunity in RSV F subunit vaccination. The vaccine is constructed based on Mn/Al-layered double hydroxide (Mn/Al-LDH) nanosheet functionalized with RSV F antigen and poly-CpG motifs. In this system, Al acts as a humoral immunity adjuvant promoting potent antibody responses, while Mn and CpG can enhance cellular immunity through activation of the cGAS-STING pathway and Toll-like receptor (TLR), respectively. The orchestrated activation of multiple immune pathways synergistically produces a “high-entropy” immunostimulatory effect, which facilitates the recruitment and subsequent activation of potent CD4+ and CD8+ T cells, thus leading to more rapid antigen-specific immune activation and fostering the establishment of robust long-term T cell memory. Furthermore, an expanded CD134-positive subset within central memory T cells (TCM) is observed, demonstrating that the immune system is primed for robust clonal proliferation and differentiation into effector and memory cell lineages. This immunological setup ensures that any subsequent encounter with the specific antigen will trigger an immediate and vigorous secondary response. In murine challenge models, the nanovaccine outperforms traditional aluminum (Al)-based vaccines by significantly reducing viral load and mitigating lung pathology. This study establishes a new paradigm for developing efficacious RSV vaccines, and the underlying strategy is broadly applicable to vaccine development against other intractable pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus VaccinesAdjuvants, ImmunologicRespiratory Syncytial Virus InfectionsRespiratory Syncytial VirusesAdjuvants, VaccineAnimalsMiceNanovaccinesVaccines, SubunitProtein Subunit VaccinesMice, Inbred BALB CFemale

Substanzen

Respiratory Syncytial Virus VaccinesAdjuvants, ImmunologicNanovaccinesVaccines, SubunitProtein Subunit VaccinesAdjuvants, Vaccine

Autor:innen und Institutionen

  • State Key Laboratory of Chemical Resource Engineering, College of Chemistry, Beijing University of Chemical Technology, Beijing100029, P. R. China.
  • Immunological Materials Research Group 1, National Vaccine and Serum Institute (NVSI), Beijing101111, P. R. China.
  • National Engineering Research Center for New Vaccine, Beijing101111, P. R. China.
  • The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing101111, P. R. China.
  • State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, Beijing101111, P. R. China.
  • Immunological Evaluation Unit, National Vaccine and Serum Institute (NVSI), Beijing101111, P.R.China.

ORCID-Profile: Guangjun Nie, Feng Li

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality
  • Beijing University of Chemical Technology
  • Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
  • National Key Research and Development Program of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Chen, L., Sun, Y., Dong, Y., Jin, Y., Han, Z., Liu, N., Zheng, X., Shao, S., Zhang, J., Liang, Y., Pu, M., Du, M., Li, Q., Nie, G., Ren, J., & Li, F. (2026). An Orthogonal Nanoadjuvant-Based RSV Subunit Vaccine Unlocks Potent Immunity through a High-Entropy-like Immunostimulatory Effect. Journal of the American Chemical Society, 148(30), 32863-32880. https://doi.org/10.1021/jacs.6c11987

Vancouver

Chen L, Sun Y, Dong Y, Jin Y, Han Z, Liu N, et al. An Orthogonal Nanoadjuvant-Based RSV Subunit Vaccine Unlocks Potent Immunity through a High-Entropy-like Immunostimulatory Effect. Journal of the American Chemical Society. 2026;148(30):32863-32880. doi:10.1021/jacs.6c11987

BibTeX
@article{Chen2026,
  author = {Chen, Ling and Sun, Yun and Dong, Yuhang and Jin, Yuqin and Han, Zibo and Liu, Ning and Zheng, Xiang and Shao, Shuai and Zhang, Jing and Liang, Yu and Pu, Mingtao and Du, Meijing and Li, Qiming and Nie, Guangjun and Ren, Jin and Li, Feng},
  title = {An Orthogonal Nanoadjuvant-Based RSV Subunit Vaccine Unlocks Potent Immunity through a High-Entropy-like Immunostimulatory Effect},
  journal = {Journal of the American Chemical Society},
  year = {2026},
  volume = {148},
  number = {30},
  pages = {32863--32880},
  doi = {10.1021/jacs.6c11987}
}
Kostenlos starten →